Zalutumumab
- Generic Name
- Zalutumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 667901-13-5
- Unique Ingredient Identifier
- DA709Q5020
- Background
Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2011-10-10
- Lead Sponsor
- Genmab
- Registration Number
- NCT01449357
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 8
- Registration Number
- NCT00707655
- Locations
- 🇫🇷
Medical Oncology, Outpatient Clinic, Nantes, France
🇬🇧Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
🇫🇷Centre Georges-Francois Leclerc Hospital, Dijon, France
Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Genmab
- Target Recruit Count
- 9
- Registration Number
- NCT00677924
- Locations
- 🇧🇪
Hospital Erasme, Brussels, Belgium
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪St-Luc University Hospital, Brussels, Belgium
Zalutumumab in Non-curable Patients With SCCHN
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 90
- Registration Number
- NCT00542308
- Locations
- 🇺🇸
University Of Chicago Medical Center, Chicago, Illinois, United States
🇦🇹Universitätsklinik für Innere Medizin III, Salzburg, Austria
🇨🇿Nemocnice Jihlava, Jihlava, Czechia
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
- Conditions
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Danish Head and Neck Cancer Group
- Target Recruit Count
- 619
- Registration Number
- NCT00496652
- Locations
- 🇩🇰
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2011-12-23
- Lead Sponsor
- Genmab
- Target Recruit Count
- 30
- Registration Number
- NCT00401401
- Locations
- 🇳🇱
Nijmegen University Hospital, Nijmegen, Netherlands
🇸🇪Lund University Hospital, Lund, Sweden
🇫🇷Centre Georges-Francois Leclerc Hospital, Dijon, France
Zalutumumab in Patients With Non-curable Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2013-10-15
- Lead Sponsor
- Genmab
- Target Recruit Count
- 286
- Registration Number
- NCT00382031
- Locations
- 🇧🇪
Cliniques Saint Pierre, Ottignies, Belgium
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇧🇷IBCC - Instituto Brasileiro de Combate ao Câncer, São Paulo, Brazil
Zalutumumab in Head and Neck Cancer
- First Posted Date
- 2004-10-01
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Genmab
- Target Recruit Count
- 28
- Registration Number
- NCT00093041
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen Ø, Denmark
🇩🇰Odense Universitetshospital, Odense, Denmark
🇩🇰Århus Kommunehospital, Århus C, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.